Sam Klempner
@KlempnerSam
Followers
5K
Following
3K
Media
220
Statuses
1K
GI medical oncologist focusing on stomach and esophageal cancer research at Massachusetts General Hospital, Harvard Medical School
Boston, MA
Joined January 2019
Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer
15
41
171
Nice way to end the week. Pre-print from our team. @arnavmehta3 @JeeyunM @AnMinae, others. Support from @SU2C @AACR. @MGHCancerCenter . Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer
medrxiv.org
The addition of aPD1 to 5-FU/platinum in advanced gastric cancer (GC) yields variable responses. To understand cooperativity between chemotherapy and immunotherapy, we previously reported a phase II...
3
1
36
RT @NatureMedicine: A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesop….
0
5
0
RT @sundar__raghav: Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by @KlempnerSam and m….
nature.com
Nature Medicine - A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal cancers and highlight the rapid expansion of...
0
17
0
Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer. Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav.
0
10
32
RT @ArndtVogel: Givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in mGEC.🔎Phase I/II.👉….
0
19
0
RT @SunnieSKim: FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the….
amgen.com
0
15
0
RT @FASinicropeMD: Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented. https….
0
12
0
RT @ElizSMcKenna: Attending the #AACR25 session on Innovative Paradigms in Immunotherapy Combos in Gastric Cancer? Read speaker @KlempnerSa….
0
5
0
Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial. @JeeyunM @AnMinae @arnavmehta3 @CCR_AACR.
1
5
40
Proof of principle in KRAS G12C CRC, analogous to EGFR rechallenge in RAS WT Colon cancer. @MGHCancerCenter @JCOPO_ASCO . Anti-KRAS G12C + Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer.
ascopubs.org
1
10
58
Cool paper from @ShadiEsfahani and team in @ScienceTM @MGHCancerCenter . Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine
science.org
Fibrin within the tumor can be used as a target for the detection and treatment of gastric cancer.
1
4
26
RT @SCIDirector: SCI members @HowardYChang, @mischellab, and others found that blocking #CHK1 activity leads to death of #ecDNA containing….
0
3
0
Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy | Journal of Clinical Oncology
ascopubs.org
1
6
48
Adding to the ever growing approaches in GEA. @JCO_ASCO @ASCO. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish |
ascopubs.org
PURPOSEThe outcomes of anti–PD-1 agents plus fluoropyrimidine/platinum in frontline advanced gastroesophageal adenocarcinomas (aGEAs) remain poor. We investigated the safety, tolerability, and...
5
18
77
Great to have another option for patients. @KoheiShitara @mdmanishshah @ILSONDavid @FlorianLordick @sara_lonardi1 and many others. FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma via @onclive.
onclive.com
The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
2
23
87
RT @KoheiShitara: Pleased to share final survival results of two phase 3 of zolbetuximab @NEJM which reinforce zolbetuxumab plus chemo as….
nejm.org
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemoth...
0
62
0
RT @sundar__raghav: Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of or….
0
26
0
Congratulations to Harsh Singh and @DanaFarber team for getting this data out. CAPOX + Trastuzumab + Bevacizumab in frontline HER2+ gastroesophageal. @NatureComms @JamesClearyMD @DrRonanKelly and others . -- full paper.
1
3
43
RT @KEN_K_: I am pleased to inform you that the primary result of JCOG1109 was published in the Lancet today. The neoadjuvant triplet chemo….
0
17
0